Get the Stockscreener App
4.525
2.89%
0.125
Prelude Therapeutics Inc stock is traded at $4.525, with a volume of 54,394.
It is up +2.89% in the last 24 hours and up +25.76% over the past month.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
See More
Previous Close:
$4.40
Open:
$4.43
24h Volume:
54,394
Relative Volume:
0.16
Market Cap:
$285.09M
Revenue:
$12.14M
Net Income/Loss:
$-99.50M
P/E Ratio:
-3.3427
EPS:
-1.3537
Net Cash Flow:
$-56.37M
1W Performance:
+30.85%
1M Performance:
+25.76%
6M Performance:
+259.31%
1Y Performance:
+605.41%
1-Day Range:
$4.34
$4.62
1-Week Range:
$3.48
$4.815
52-Week Range:
$0.6445
$4.815
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics Inc
Sector
Industry
Phone
(302) 467-1280
Address
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
4.525 | 265.87M | 12.14M | -99.50M | -56.37M | -1.3537 |
VRTX
Vertex Pharmaceuticals Inc
|
444.52 | 112.92B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.51 | 81.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
805.09 | 48.82B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
326.81 | 43.66B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.62 | 34.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-20-24 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-13-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-20-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-29-22 | Initiated | Jefferies | Buy |
| Mar-15-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-28-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-27-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-26-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Nov-20-20 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Goldman | Neutral |
| Oct-20-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prelude Therapeutics Inc Stock (PRLD) Latest News
Retail Surge: Is Prelude Therapeutics Incorporated a turnaround story2026 Drop Watch & Consistent Income Trade Recommendations - baoquankhu1.vn
Loss Report: How do insiders feel about Prelude Therapeutics IncorporatedExit Point & Scalable Portfolio Growth Methods - baoquankhu1.vn
IPO Launch: Will Prelude Therapeutics Incorporated stock go up in YEARMarket Performance Recap & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Prelude Therapeutics Incorporated (PRLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PRLD Technical Analysis | Trend, Signals & Chart Patterns | PRELUDE THERAPEUTICS INC (NASDAQ:PRLD) - ChartMill
Prelude Therapeutics reports 2025 results and advances oncology pipeline - MSN
PRLD Technical Analysis & Stock Price Forecast - Intellectia AI
Rate Hike: Is Prelude Therapeutics Incorporated backed by strong institutional buying2026 Drop Watch & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Marker Therapeutics (NASDAQ:MRKR) & Prelude Therapeutics (NASDAQ:PRLD) Financial Survey - Defense World
If You Invested $1,000 in Prelude Therapeutics Inc (PRLD) - Stock Titan
PRLD PE Ratio & Valuation, Is PRLD Overvalued - Intellectia AI
Value Recap: How do insiders feel about Prelude Therapeutics IncorporatedChart Signals & Community Consensus Trade Alerts - baoquankhu1.vn
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting - Yahoo Finance
Prelude Therapeutics Reports 2025 Results and Advances Oncology Pipeline - MyChesCo
Prelude Therapeutics Inc. Files Form 8-K with SEC – Company Information and Legal Exhibit Details (March 12, 2026) - Minichart
Prelude Therapeutics Establishes New ATM Equity Offering Facility - The Globe and Mail
Prelude Therapeutics files to offer up to $25 million in stock through Jefferies By Investing.com - Investing.com South Africa
Prelude Therapeutics files to offer up to $25 million in stock through Jefferies - Investing.com
Prelude Therapeutics 2025 Annual Report: Precision Oncology Pipeline, Business Strategy, and Regulatory Overview - Minichart
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8% - AlphaStreet
ADC Therapeutics SA (ADCT) Reports Wider Loss Q4 EPS Estimates by 85.1% - AlphaStreet
Prelude Therapeutics (NASDAQ:PRLD) Price Target Raised to $6.00 at Citizens Jmp - MarketBeat
Citizens Analyst Raises Price Target for Prelude Therapeutics (P - GuruFocus
Citizens raises Prelude Therapeutics price target on JAK2 potential By Investing.com - Investing.com Canada
Prelude Therapeutics (PRLD) Q4 Loss Per Share Narrows Challenging Longstanding Bearish Narratives - simplywall.st
PRLD: Pipeline refocused on JAK2 V617F and KAT6A, with strong funding and key Incyte partnership - TradingView
Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings - AlphaStreet
Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M - AlphaStreet
Prelude Therapeutics Inc (PRLD) Reports Wider Loss for FY25 vs. Estimates - AlphaStreet
Prelude Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Prelude Therapeutics 2025 10-K: Revenue $12.14M, EPS (1.29) - TradingView
Prelude Therapeutics (NASDAQ:PRLD) Posts Quarterly Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat
PRLD: Secured $60M upfront from Incyte, boosting cash and extending runway into Q2 2027 - TradingView
Prelude Therapeutics (PRLD) Advances Key Drug Programs with IND Clearance - GuruFocus
Prelude Therapeutics Earnings Report: Q4 Overview - Benzinga
Prelude Therapeutics reports $99.5 mln net loss for 2025 - TradingView
BRIEF-Prelude Therapeutics FY EPS USD -1.29 - TradingView
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 - ChartMill
Aug Analyst Calls: Can Prelude Therapeutics Incorporated outperform under higher oil prices2025 Risk Factors & Fast Gain Swing Alerts - baoquankhu1.vn
Prelude Therapeutics Inc expected to post a loss of 3 cents a shareEarnings Preview - TradingView
Volume Report: Is Prelude Therapeutics Incorporated a cyclical or defensive stockQuarterly Earnings Report & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Prelude Therapeutics (PRLD) Expected to Announce Earnings on Monday - MarketBeat
PRLD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Market Wrap: Is Prelude Therapeutics Incorporated backed by strong institutional buyingMarket Performance Summary & Expert Verified Movement Alerts - baoquankhu1.vn
Quarterly Risk: Does Prelude Therapeutics Incorporated have consistent dividend growthJuly 2025 Earnings & Safe Capital Allocation Plans - baoquankhu1.vn
PRLDPrelude Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Guidance Update: Is Prelude Therapeutics Incorporated stock trending bullishTreasury Yields & Technical Entry and Exit Alerts - baoquankhu1.vn
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update - MarketBeat
How Prelude Therapeutics’ deal with Incyte changed its course - Delaware Business Times
What’s the beta of Prelude Therapeutics Incorporated stock2025 AllTime Highs & AI Powered Market Entry Strategies - mfd.ru
Aug Chart Watch: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesGlobal Markets & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Prelude Therapeutics Inc Stock (PRLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):